Sign In
Last checked at 
3 May 2022 16:46
PDMR Dealings
Oxford, UK - 03 May 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB), was informed on 03 May 2022, that Dr. Jason Slingsby, Chief Business & Corporate Development Officer of the Group, exercised 8,712 LTIP (2018) options at nil cost on 27 April 2022, and sold all the resulting ordinary shares at 539.0p per share. Following this transaction Dr. Jason Slingsby continues to hold 120,476 options over ordinary shares.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold.
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
a) | Name | Jason Slingsby | ||||
2. | Reason for the notification | |||||
a) | Position/status | Chief Business & Corporate Development Officer
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford BioMedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Options over ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Exercise of options at nil cost | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s) |
| ||||
e) | Aggregated information - Aggregate volume
- Price
- Aggregated total
|
8,712
Nil
Nil | ||||
f) | Date of the transaction | 2022-04-27 | ||||
g) | Place of the transaction | Outside a trading venue | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
a) | Name | Jason Slingsby | ||||
2. | Reason for the notification | |||||
a) | Position/status | Chief Business & Corporate Development Officer
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford BioMedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Disposal | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s) |
| ||||
e) | Aggregated information - Aggregate volume
- Price
- Aggregated total
|
8,712
£5.39
£46,957.68 | ||||
f) | Date of the transaction | 2022-04-27 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
-Ends-
For further information, please contact: |
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.
Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com .
Follow the stocks
